Literature DB >> 26355060

Overcoming Obstacles To Enable Access To Medicines For Noncommunicable Diseases In Poor Countries.

Sandeep P Kishore1, Kavitha Kolappa2, Jordan D Jarvis3, Paul H Park4, Rachel Belt5, Thirukumaran Balasubramaniam6, Rachel Kiddell-Monroe7.   

Abstract

The modern access-to-medicines movement grew largely out of the civil-society reaction to the HIV/AIDS pandemic three decades ago. While the movement was successful with regard to HIV/AIDS medications, the increasingly urgent challenge to address access to medicines for noncommunicable diseases has lagged behind-and, in some cases, has been forgotten. In this article we first ask what causes the access gap with respect to lifesaving essential noncommunicable disease medicines and then what can be done to close the gap. Using the example of the push for access to antiretrovirals for HIV/AIDS patients for comparison, we highlight the problems of inadequate global financing and procurement for noncommunicable disease medications, intellectual property barriers and concerns raised by the pharmaceutical industry, and challenges to building stronger civil-society organizations and a patient and humanitarian response from the bottom up to demand treatment. We provide targeted policy recommendations, specific to the public sector, the private sector, and civil society, with the goal of improving access to noncommunicable disease medications globally. Project HOPE—The People-to-People Health Foundation, Inc.

Entities:  

Keywords:  Access To Care; Chronic Care; Health Economics; International/global health studies

Mesh:

Substances:

Year:  2015        PMID: 26355060     DOI: 10.1377/hlthaff.2015.0375

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  8 in total

1.  Mapping actions to improve access to medicines for mental disorders in low and middle income countries.

Authors:  C Barbui; T Dua; K Kolappa; B Saraceno; S Saxena
Journal:  Epidemiol Psychiatr Sci       Date:  2017-01-09       Impact factor: 6.892

2.  Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff.

Authors:  David Flood; Irène Mathieu; Anita Chary; Pablo García; Peter Rohloff
Journal:  BMC Health Serv Res       Date:  2017-01-13       Impact factor: 2.655

3.  Improving access to medicines via the Health Impact Fund in India: a stakeholder analysis.

Authors:  Patrick McMullan; Vamadevan S Ajay; Ravi Srinivas; Sandeep Bhalla; Dorairaj Prabhakaran; Amitava Banerjee
Journal:  Glob Health Action       Date:  2018       Impact factor: 2.640

4.  Disparities in availability of essential medicines to treat non-communicable diseases in Uganda: A Poisson analysis using the Service Availability and Readiness Assessment.

Authors:  Mari Armstrong-Hough; Sandeep P Kishore; Sarah Byakika; Gerald Mutungi; Marcella Nunez-Smith; Jeremy I Schwartz
Journal:  PLoS One       Date:  2018-02-08       Impact factor: 3.240

5.  Coronavirus Disease Pandemic Effect on Medical-Seeking Behaviors Even in One Resource-Competent Community: A Case Controlled Study.

Authors:  Fang Wang; Jin-Ming Wu; Yi-Chieh Lin; Te-Wei Ho; Hui-Lin Lin; Hsi-Yu Yu; I-Rue Lai
Journal:  Int J Environ Res Public Health       Date:  2022-08-30       Impact factor: 4.614

6.  Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group.

Authors:  William A Gahl; Durhane Wong-Rieger; Virginie Hivert; Rachel Yang; Galliano Zanello; Stephen Groft
Journal:  Orphanet J Rare Dis       Date:  2021-07-13       Impact factor: 4.123

7.  Barriers to global health development: An international quantitative survey.

Authors:  Bahr Weiss; Amie Alley Pollack
Journal:  PLoS One       Date:  2017-10-03       Impact factor: 3.240

Review 8.  National adaptation and implementation of WHO Model List of Essential Medicines: A qualitative evidence synthesis.

Authors:  Elizabeth F Peacocke; Sonja L Myhre; Hakan Safaralilo Foss; Unni Gopinathan
Journal:  PLoS Med       Date:  2022-03-11       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.